Oncolytics Biotech Inc.
ONC.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.72M | 10.03M | 11.65M | 11.77M | 11.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.55M | 26.02M | 27.00M | 26.54M | 25.05M |
| Operating Income | -25.55M | -26.02M | -27.00M | -26.54M | -25.05M |
| Income Before Tax | -23.05M | -20.21M | -20.61M | -20.88M | -20.53M |
| Income Tax Expenses | 94.60K | 109.80K | 106.20K | 71.80K | 71.80K |
| Earnings from Continuing Operations | -23.14 | -20.32 | -20.72 | -20.95 | -20.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.14M | -20.32M | -20.72M | -20.95M | -20.60M |
| EBIT | -25.55M | -26.02M | -27.00M | -26.54M | -25.05M |
| EBITDA | -25.47M | -25.94M | -26.93M | -26.48M | -24.99M |
| EPS Basic | -0.30 | -0.27 | -0.28 | -0.30 | -0.31 |
| Normalized Basic EPS | -0.19 | -0.17 | -0.18 | -0.19 | -0.19 |
| EPS Diluted | -0.30 | -0.27 | -0.28 | -0.30 | -0.31 |
| Normalized Diluted EPS | -0.19 | -0.17 | -0.18 | -0.19 | -0.19 |
| Average Basic Shares Outstanding | 305.92M | 302.15M | 294.94M | 283.31M | 270.41M |
| Average Diluted Shares Outstanding | 305.92M | 302.15M | 294.94M | 283.31M | 270.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |